U.S., Dec. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07269912) titled 'Application of Multimodal MRI in Histological Grading and Prognostic Assessment of Rectal Cancer' on Nov. 26.
Brief Summary: Rectal cancer (RC) is among the most prevalent gastrointestinal cancers [1], characterized by significant tumor heterogeneity [2]. Neoadjuvant chemoradiotherapy followed by total mesorectal excision is a standard treatment for locally advanced rectal cancer [3]. Although the locoregional recurrence rate has decreased due to this treatment, distant metachronous metastases still occur in over 20-30% of cases [4,5]. The varying biological characteristics of rectal cancer may result in different treatment responses...